NeftalyApp Courses Partner Invest Corporate Charity Divisions

Neftaly Email: sayprobiz@gmail.com Call/WhatsApp: + 27 84 313 7407

Tag: disease

Neftaly Email: sayprobiz@gmail.com Call/WhatsApp: + 27 84 313 7407

[Contact Neftaly] [About Neftaly][Services] [Recruit] [Agri] [Apply] [Login] [Courses] [Corporate Training] [Study] [School] [Sell Courses] [Career Guidance] [Training Material[ListBusiness/NPO/Govt] [Shop] [Volunteer] [Internships[Jobs] [Tenders] [Funding] [Learnerships] [Bursary] [Freelancers] [Sell] [Camps] [Events&Catering] [Research] [Laboratory] [Sponsor] [Machines] [Partner] [Advertise]  [Influencers] [Publish] [Write ] [Invest ] [Franchise] [Staff] [CharityNPO] [Donate] [Give] [Clinic/Hospital] [Competitions] [Travel] [Idea/Support] [Events] [Classified] [Groups] [Pages]

  • Neftaly Inpatient care patterns for Parkinson’s disease exacerbations

    Neftaly Inpatient care patterns for Parkinson’s disease exacerbations

    Neftaly: Inpatient Care Patterns for Parkinson’s Disease Exacerbations

    1. Introduction & Significance

    • Parkinson’s Disease (PD) patients are hospitalized more frequently and tend to have longer inpatient stays compared to non‑PD patients.jmust.orgmovementdisorders.onlinelibrary.wiley.com
    • Although only about 15% of these admissions are directly due to PD-related complications, many admissions stem from secondary issues like pneumonia and falls, which exacerbate PD symptoms.jmust.orgmovementdisorders.onlinelibrary.wiley.com
    • During hospitalizations, PD symptoms can worsen due to factors such as infections, medication disruptions, anesthesia exposure, or other metabolic and environmental stressors.jmust.org

    2. Common Triggers and Reasons for Exacerbations

    • Infections: Aspiration pneumonia, urinary tract infections, and sepsis are frequent reasons for admission and symptom aggravation.PubMedPMC
    • Falls and trauma: Gait instability and postural issues often result in injuries requiring hospitalization.practicalneurology.comPubMed
    • Medication changes: Being NPO, mis-timed administration, or hospital routines that differ from home regimens can destabilize motor control.The Pharmaceutical Journaljmust.org
    • Delirium and autonomic issues: Hospital stress increases risk of delirium, orthostatic hypotension, and other autonomic dysfunctions.PMCpracticalneurology.com

    3. Key Inpatient Care Patterns

    3.1 Medication Management

    • Timing is critical: Levodopa and similar anti-Parkinson’s medications have short half-lives and require precise timing. Delays or omissions often lead to motor deterioration or dyskinesias.jmust.orgThe Pharmaceutical Journal
    • Medication mismatches are common: Up to 50% of PD patients experience missed doses, with 30% receiving medication an hour late.jmust.org
    • Best practices include:
      • Never discontinuing PD medications without a substitute.
      • Prioritizing accurate dose reconciliation within 24 hours of admission.
      • Involving PD nurse specialists and pharmacy teams early.The Pharmaceutical JournalFrontiers
    • Optimizing workflows through interventions:
      • Pharmacist-led initiatives that align inpatient medication timing with home regimens reduced length of stay, falls, readmissions, and mortality.PubMed
      • Dedicated inpatient teams (nurse practitioners and pharmacists) ensure custom scheduling and medication delivery, and prevent contraindicated drugs.Neurology live

    3.2 Multidisciplinary & Supportive Care

    • Preventing aspiration: Speech and language therapists can help with swallowing strategies (e.g., chin tuck, modified textures) especially when anti-Parkinson medications are administered.practicalneurology.com
    • Fall mitigation: Addressing motor fluctuations and providing physical therapy and home safety evaluations are vital. Adjusting levodopa dosing frequency—while balancing orthostatic effects—is often necessary.practicalneurology.com
    • Avoiding contraindicated medications: Drugs worsened PD (e.g., metoclopramide, haloperidol) should be avoided. Early medicines reconciliation and pharmacist review are key.The Pharmaceutical JournalNeurology live

    4. Outcomes & Metrics from Inpatient Data

    Epidemiological Trends (U.S., 2002–2011):

    • Over 3 million PD-related hospital admissions were documented.
    • In-hospital mortality declined from 4.9% to 3.3%.
    • Median length of stay dropped from 3.6 days to 2.3 days.
    • Adjusted hospital costs rose from $22,250 to $37,942.PubMed

    Comparative Outcome Metrics:

    • PD patients face elevated risks during hospitalization:
      • Higher odds of aspiration pneumonia and delirium.
      • Increased likelihood of early Do-Not-Resuscitate orders.
      • Greater need for interventions like tracheostomy and gastrostomy.
      • More frequent discharge to nursing facilities.
      • Slightly greater in‑hospital mortality compared to matched controls.PMC

    Impact of Depression:

    • PD patients with comorbid major depressive disorder (MDD) show:
      • Longer hospital stays (median 5.85 vs. 4.08 days).
      • Elevated in‑hospital mortality (1.4% vs. 1.1%).
      • Increased likelihood of being transferred to acute care.
      • Lower rates of therapeutic procedures (e.g., Deep Brain Stimulation).PubMed

    5. Synthesis Table: Inpatient Care Patterns & Outcomes

    ComponentCare PatternImpact / Outcome
    Medication timingPrecise home-timed dosing via pharmacy/nurse-led protocolsReduced motor deterioration, falls, readmissions, and mortalityPubMedNeurology live
    Multidisciplinary supportSpeech therapy, PT, pharmacist and PD nurse involvementReduced aspiration, falls, adverse medication eventspracticalneurology.comThe Pharmaceutical JournalNeurology live
    Complication riskAttention to infections, delirium, autonomic dysfunctionsLower mortality, ICU interventions, nursing home placementPMCPubMed
    Comorbid depressionGreater length of stay and mortality, fewer proceduresIndicates need for psychological screening and tailored supportPubMed

    6. Practice Implications

    • Medication accuracy → Safety: Aligning inpatient regimens with home medications is foundational to care quality.
    • Early multidisciplinary involvement: Pharmacists, PD nurse specialists, and therapists reduce risk of complications.
    • Monitor nonmotor complications: Proactively addressing dysphagia, autonomic instability, and delirium improves outcomes.
    • Address psychosocial factors: Screening and managing depression and mental health comorbidities may reduce hospital burden and improve therapy uptake.
    • Track and innovate metrics: Hospital programs should monitor length of stay, adverse events, readmissions, and patient satisfaction (all responsive to care patterns).

    7. Conclusion

    Inpatient care for PD exacerbations benefits greatly from attention to medication fidelity, team-based support, and prevention of complication cascades. Though hospitalization rates and costs are rising, efforts optimizing inpatient protocols—especially around medication timing and multidisciplinary care—demonstrate tangible improvements in outcomes, safety, and patient satisfaction.

  • Neftaly Clinical approaches to managing chronic liver disease complications

    Neftaly Clinical approaches to managing chronic liver disease complications

    Clinical Approaches to Managing Chronic Liver Disease Complications

    Introduction

    Chronic liver disease (CLD) encompasses a range of progressive liver conditions—such as chronic hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and cirrhosis—that can lead to severe complications if left unmanaged. These complications, including portal hypertension, hepatic encephalopathy, ascites, and variceal bleeding, significantly increase morbidity and mortality.

    At Neftaly, we highlight comprehensive, evidence-based clinical strategies to manage chronic liver disease complications effectively, aiming to improve patient outcomes and quality of life.


    Understanding Chronic Liver Disease Complications

    Chronic liver disease often progresses silently until complications arise. Common complications include:

    • Ascites: Accumulation of fluid in the abdominal cavity due to portal hypertension
    • Hepatic Encephalopathy (HE): Neuropsychiatric disturbances caused by the accumulation of toxins like ammonia
    • Variceal Bleeding: Life-threatening hemorrhage from esophageal or gastric varices
    • Hepatorenal Syndrome (HRS): Kidney dysfunction secondary to advanced liver disease
    • Coagulopathy and Thrombocytopenia: Impaired liver synthesis of clotting factors
    • Hepatocellular Carcinoma (HCC): Primary liver cancer as a late-stage complication

    Clinical Management Strategies

    1. Ascites Management

    • Dietary Sodium Restriction: <2g per day to reduce fluid retention
    • Diuretics: Spironolactone (± furosemide) to promote fluid loss while maintaining electrolyte balance
    • Therapeutic Paracentesis: Removal of large-volume ascites with albumin infusion to prevent circulatory dysfunction
    • Transjugular Intrahepatic Portosystemic Shunt (TIPS): Considered for refractory ascites

    2. Hepatic Encephalopathy (HE)

    • Lactulose: First-line treatment to reduce ammonia absorption in the gut
    • Rifaximin: A non-absorbable antibiotic used in combination with lactulose to prevent recurrent HE
    • Nutritional Support: Maintain adequate protein intake while managing precipitating factors (e.g., GI bleeding, infection, constipation)

    3. Variceal Bleeding

    • Primary Prophylaxis: Non-selective beta-blockers (e.g., propranolol or nadolol) or endoscopic variceal ligation (EVL) in high-risk patients
    • Acute Bleed Management: Volume resuscitation, vasoactive agents (e.g., octreotide), endoscopic therapy, and antibiotic prophylaxis
    • Secondary Prophylaxis: Combination of beta-blockers and repeat EVL to prevent rebleeding

    4. Hepatorenal Syndrome (HRS)

    • Volume Expansion: With albumin to improve renal perfusion
    • Vasoconstrictors: Terlipressin or norepinephrine to increase renal blood flow
    • Renal Replacement Therapy: May be necessary in advanced cases
    • Liver Transplantation: Definitive treatment in eligible patients

    5. Coagulopathy and Thrombocytopenia

    • Monitoring Bleeding Risk: Avoid unnecessary procedures; use platelets or fresh frozen plasma only if bleeding or invasive procedures are planned
    • Thrombopoietin Receptor Agonists: Considered for severely low platelet counts

    6. Hepatocellular Carcinoma (HCC) Surveillance and Management

    • Surveillance: Ultrasound (± alpha-fetoprotein) every 6 months in high-risk patients
    • Treatment Options: Resection, liver transplantation, radiofrequency ablation, transarterial chemoembolization (TACE), and systemic therapy (e.g., sorafenib, immunotherapy)

    Multidisciplinary and Supportive Care

    • Nutrition Counseling: Address protein-calorie malnutrition common in advanced liver disease
    • Infection Prevention: Vaccinate against hepatitis A and B; monitor for spontaneous bacterial peritonitis (SBP)
    • Psychosocial Support: Address mental health, substance use, and caregiver burden
    • Liver Transplant Evaluation: Early referral for transplant eligibility assessment is crucial in end-stage disease

    Conclusion

    Effective management of chronic liver disease complications requires a multidisciplinary, patient-centered approach. Early recognition and timely intervention are key to reducing morbidity and improving survival. Ongoing monitoring, patient education, and coordination across healthcare teams enhance long-term outcomes.

    Neftaly is committed to equipping healthcare providers with the latest clinical insights, tools, and training to manage chronic liver disease complications with confidence and compassion.

  • Neftaly The impact of telemedicine on chronic disease follow-up care

    Neftaly The impact of telemedicine on chronic disease follow-up care

    The Impact of Telemedicine on Chronic Disease Follow-Up Care

    Introduction

    Chronic diseases such as diabetes, hypertension, heart disease, and chronic respiratory conditions require ongoing management and regular follow-up to prevent complications and improve quality of life. Traditionally, follow-up care has involved frequent in-person visits, which can be burdensome for patients and healthcare systems alike.

    With the rapid advancement of technology, telemedicine has emerged as a transformative tool in chronic disease management. At Neftaly, we explore how telemedicine is reshaping follow-up care by enhancing accessibility, improving patient engagement, and optimizing healthcare delivery.


    Benefits of Telemedicine in Chronic Disease Follow-Up

    1. Improved Access and Convenience

    Telemedicine removes geographical and logistical barriers, allowing patients—especially those in rural or underserved areas—to receive timely follow-up care without the need for travel. This flexibility reduces missed appointments and supports continuous monitoring.

    2. Enhanced Patient Engagement and Self-Management

    Virtual consultations and remote monitoring tools empower patients to take an active role in managing their health. Real-time feedback and digital health education increase adherence to treatment plans and promote lifestyle modifications critical for disease control.

    3. Early Detection and Intervention

    Remote monitoring devices (e.g., glucometers, blood pressure cuffs, pulse oximeters) integrated with telemedicine platforms enable continuous data collection. Healthcare providers can detect early signs of deterioration and intervene promptly, reducing hospitalizations and emergency visits.

    4. Cost-Effectiveness

    Telemedicine reduces indirect costs such as transportation, lost work hours, and caregiver burden. Healthcare systems benefit from optimized resource utilization and decreased demand for in-person services.

    5. Continuity and Coordination of Care

    Telemedicine facilitates seamless communication among multidisciplinary care teams. Coordinated follow-up across specialists, primary care, and allied health professionals improves comprehensive chronic disease management.


    Challenges and Considerations

    While telemedicine offers significant advantages, challenges remain:

    • Ensuring equitable access to technology and internet connectivity
    • Protecting patient privacy and data security
    • Addressing limitations in physical examination and diagnostic testing remotely
    • Training healthcare providers and patients to effectively use telehealth tools

    Future Directions

    Advancements such as artificial intelligence, wearable health technologies, and integrated electronic health records promise to further enhance telemedicine’s role in chronic disease follow-up. Personalized, predictive care models powered by data analytics will support proactive disease management and improved outcomes.


    Conclusion

    Telemedicine is revolutionizing chronic disease follow-up care by making it more accessible, patient-centered, and efficient. As healthcare systems continue to integrate virtual care, the potential to improve disease control and reduce healthcare costs grows substantially.

    At Neftaly, we are committed to supporting healthcare providers and organizations in leveraging telemedicine technologies to deliver high-quality, sustainable chronic disease management.

  • Neftaly Advances in clinical infectious disease treatment protocols

    Neftaly Advances in clinical infectious disease treatment protocols

    Advances in Clinical Infectious Disease Treatment Protocols

    Infectious diseases remain a major global health challenge, particularly in regions with high burdens of HIV, tuberculosis (TB), malaria, and emerging viral threats. As pathogens evolve and antimicrobial resistance continues to rise, the need for innovative, evidence-based treatment protocols is more urgent than ever.

    At Neftaly, we are committed to advancing healthcare delivery through the dissemination and implementation of the latest clinical standards. This includes assessing and promoting cutting-edge infectious disease treatment protocols that improve outcomes, reduce mortality, and support health system resilience.

    The Changing Landscape of Infectious Disease Management

    Infectious disease treatment has evolved rapidly due to breakthroughs in:

    • Diagnostics (rapid testing, point-of-care technologies)
    • Pharmacology (new antimicrobial agents, antiviral therapies)
    • Vaccine development (especially mRNA and vector-based platforms)
    • Clinical research (real-world evidence and adaptive clinical trials)

    These advances have paved the way for updated treatment protocols that are more personalized, targeted, and efficient.

    Key Advances in Treatment Protocols

    1. Antimicrobial Stewardship and Resistance Mitigation

    Modern protocols prioritize the responsible use of antibiotics and antifungals to slow the spread of antimicrobial resistance (AMR). This includes:

    • Narrow-spectrum therapies based on rapid diagnostics
    • De-escalation strategies once pathogens are identified
    • Institutional antimicrobial stewardship programs (ASPs)

    2. Integrated HIV and TB Treatment

    South Africa and other high-burden countries have adopted integrated treatment protocols for co-infected individuals, including:

    • Same-day antiretroviral therapy (ART) initiation
    • Shorter, more tolerable TB treatment regimens
    • Use of dolutegravir-based combinations for ART
    • Improved adherence support through community health workers

    3. Management of Emerging and Re-emerging Infections

    Protocols now include contingency plans for outbreaks of diseases such as COVID-19, Ebola, and Monkeypox. These include:

    • Use of repurposed and novel antivirals (e.g., remdesivir, molnupiravir)
    • Monoclonal antibody therapies
    • Updated isolation and infection control measures
    • Clear triage and treatment algorithms

    4. Personalized Treatment Approaches

    New protocols are increasingly personalized based on:

    • Patient comorbidities
    • Drug resistance profiles
    • Immune status (especially in immunocompromised patients)
    • Genomic and biomarker data (when available)

    5. Community-Based Treatment Models

    Recognizing the importance of access and equity, protocols now emphasize decentralised, community-driven models, including:

    • Mobile health units
    • Community ART groups (CAGs)
    • Digital tools for treatment monitoring and adherence

    Neftaly’s Role in Protocol Development and Dissemination

    Neftaly collaborates with public health authorities, academic institutions, and clinical experts to:

    • Develop and update clinical treatment guidelines based on the latest global and local data
    • Train healthcare workers through workshops, CPD programs, and digital platforms
    • Monitor implementation and treatment outcomes in real-world settings
    • Support innovation in care delivery models and therapeutic options

    Impact and Outcomes

    The implementation of advanced infectious disease treatment protocols has led to:

    • Reduced morbidity and mortality rates
    • Shorter hospital stays and improved cost-efficiency
    • Increased treatment adherence and viral suppression
    • Better preparedness for future epidemics and pandemics

    Looking Ahead

    As new pathogens emerge and resistance patterns shift, Neftaly remains at the forefront of clinical excellence and innovation. Our mission is to ensure that healthcare professionals have the tools, knowledge, and resources they need to deliver high-quality care in the face of ever-changing infectious disease threats.

    Conclusion

    Advancing clinical treatment protocols is not only about keeping up with science—it’s about saving lives, empowering healthcare workers, and building stronger, more responsive health systems. Neftaly is proud to be part of that journey.

  • Neftaly Clinical approaches to managing pediatric liver disease

    Neftaly Clinical approaches to managing pediatric liver disease

    Clinical Approaches to Managing Pediatric Liver Disease

    Pediatric liver disease encompasses a wide spectrum of conditions, ranging from congenital abnormalities and metabolic disorders to infectious and autoimmune hepatitis. The clinical management of these conditions requires a multidisciplinary approach tailored to the unique physiology, growth considerations, and long-term outcomes of children.

    At Neftaly, we prioritize the development and dissemination of evidence-based clinical practices that improve early diagnosis, intervention, and comprehensive care for children living with liver disease.


    Understanding Pediatric Liver Disease

    Unlike adult liver disease, pediatric liver disorders are often genetic, developmental, or idiopathic in nature. Common conditions include:

    • Biliary atresia
    • Neonatal hepatitis
    • Autoimmune hepatitis
    • Metabolic liver diseases (e.g., Wilson’s disease, alpha-1 antitrypsin deficiency)
    • Viral hepatitis (e.g., Hepatitis B and C)
    • Nonalcoholic fatty liver disease (NAFLD)

    Early detection and appropriate intervention are crucial to prevent progression to liver fibrosis, cirrhosis, or liver failure.


    Neftaly’s Clinical Approach: A Multidisciplinary Model

    Neftaly promotes a structured, stepwise clinical framework for managing pediatric liver disease that includes:

    1. Early Diagnosis and Screening

    • Neonatal screening for metabolic and genetic liver diseases
    • Ultrasound and liver function tests in infants with prolonged jaundice
    • Non-invasive fibrosis assessment (e.g., elastography, FibroScan)
    • Genetic testing for inherited liver disorders

    2. Comprehensive Medical Management

    Treatment protocols depend on the underlying etiology and include:

    • Nutritional support to manage malabsorption and growth failure
    • Immunosuppressive therapy for autoimmune hepatitis
    • Antiviral therapy for chronic Hepatitis B and C
    • Ursodeoxycholic acid for cholestatic liver disease
    • Chelation therapy in conditions like Wilson’s disease

    3. Monitoring and Supportive Care

    • Regular growth and development monitoring
    • Liver function tracking through scheduled blood work
    • Management of complications such as portal hypertension, ascites, or hepatic encephalopathy
    • Psychosocial support for children and families navigating chronic disease

    4. Surgical Interventions

    • Kasai portoenterostomy for biliary atresia
    • Liver transplantation in end-stage liver disease, with pre- and post-transplant care protocols

    5. Integrated Multidisciplinary Care Teams

    Neftaly advocates for integrated teams involving:

    • Pediatric hepatologists
    • Surgeons
    • Dietitians
    • Psychologists
    • Social workers
    • Community health workers (for long-term follow-up)

    Training and Capacity Building

    Neftaly is actively involved in:

    • Training healthcare professionals on the latest pediatric liver disease management protocols
    • Developing clinical guidelines and decision-making tools
    • Supporting telehealth platforms to extend expert care to rural and underserved areas
    • Promoting community awareness and caregiver education for early symptom recognition

    Challenges and Future Directions

    While progress has been made, pediatric liver care continues to face challenges such as:

    • Delayed diagnosis in rural settings
    • Limited access to pediatric hepatology expertise and transplantation facilities
    • Socioeconomic barriers to long-term care adherence

    Neftaly is working with healthcare systems, NGOs, and government agencies to close these gaps and ensure equitable access to care.


    Conclusion

    Pediatric liver disease, if diagnosed and managed early, can often be treated effectively—preventing lifelong complications and improving quality of life. Neftaly is committed to strengthening clinical capacity, advancing protocols, and ensuring that every child receives timely, expert, and compassionate care.

    Together, we can improve outcomes for children with liver disease—one clinical advancement at a time.